Abstract

The human T-cell lymphotropic virus type 1 (HTLV-1) was the first retrovirus identified in humans, and is the causal agent of HTLV-1-associated myelopathy (also known as tropical spastic paraparesis [HAM/TSP]) and adult T-cell leukemia/lymphoma (ATLL). HTLV-1 has been neglected mainly due to the misconception that it is a low morbidity viral infection. Recently evidence has been accumulating that a large percentage of HTLV-1-infected subjects, previously only considered as carriers, have disease due to the virus, such as sicca syndrome, chronic periodontitis, overactive bladder, erectile dysfunction, uveitis, and HTLV-1-associated arthropathy.1 It is estimated that approximately 20 million individuals are infected by HTLV-1 worldwide; Brazil is considered to be the country with the highest number of cases. Epidemiologic studies have pointed out that HTLV-1 is documented in all states of Brazil.2 In this issue of the Revista Brasileira de Hematologia e Hemoterapia a seroepidemiologic study showed a prevalence of 0.15% of HLTV-1 infection among blood donors in the State of Maranhao.3 Moreover, there was a high percentage (68.6%) of co-infected individuals with hepatitis B virus (HBV). Epidemiologic studies performed over 20 years in Brazil have contributed to evaluate the changes in the prevalence Scientific comment

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call